Deciphera Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Deciphera Pharmaceuticals is Steve Hoerter, benoemd in Mar2019, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.01M, bestaande uit 12.3% salaris en 87.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.084% van de aandelen van het bedrijf, ter waarde $ 1.86M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 9 jaar.
Belangrijke informatie
Steve Hoerter
Algemeen directeur
US$6.0m
Totale compensatie
Percentage CEO-salaris | 12.3% |
Dienstverband CEO | 5.3yrs |
Eigendom CEO | 0.08% |
Management gemiddelde ambtstermijn | 4.3yrs |
Gemiddelde ambtstermijn bestuur | 9yrs |
Recente managementupdates
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$190m |
Dec 31 2023 | US$6m | US$738k | -US$195m |
Sep 30 2023 | n/a | n/a | -US$194m |
Jun 30 2023 | n/a | n/a | -US$187m |
Mar 31 2023 | n/a | n/a | -US$182m |
Dec 31 2022 | US$4m | US$703k | -US$179m |
Sep 30 2022 | n/a | n/a | -US$221m |
Jun 30 2022 | n/a | n/a | -US$258m |
Mar 31 2022 | n/a | n/a | -US$286m |
Dec 31 2021 | US$9m | US$676k | -US$300m |
Sep 30 2021 | n/a | n/a | -US$274m |
Jun 30 2021 | n/a | n/a | -US$258m |
Mar 31 2021 | n/a | n/a | -US$255m |
Dec 31 2020 | US$8m | US$650k | -US$266m |
Sep 30 2020 | n/a | n/a | -US$271m |
Jun 30 2020 | n/a | n/a | -US$263m |
Mar 31 2020 | n/a | n/a | -US$218m |
Dec 31 2019 | US$9m | US$435k | -US$192m |
Sep 30 2019 | n/a | n/a | -US$157m |
Jun 30 2019 | n/a | n/a | -US$126m |
Mar 31 2019 | n/a | n/a | -US$126m |
Dec 31 2018 | US$447k | n/a | -US$100m |
Compensatie versus markt: De totale vergoeding ($USD 6.01M ) Steve } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van Steve is gestegen terwijl het bedrijf verliesgevend is.
CEO
Steve Hoerter (53 yo)
5.3yrs
Tenure
US$6,010,712
Compensatie
Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 5.3yrs | US$6.01m | 0.084% $ 1.9m | |
Executive VP | 9.3yrs | US$2.03m | 0.049% $ 1.1m | |
Executive VP & Chief Scientific Officer | less than a year | US$3.06m | 0% $ 0 | |
Senior VP & Chief Commercial Officer | 5.8yrs | US$1.58m | 0.036% $ 801.7k | |
Executive VP & Chief Medical Officer | 4.7yrs | US$2.13m | 0.084% $ 1.8m | |
Senior VP & Chief Technical Officer | less than a year | geen gegevens | geen gegevens | |
Senior Vice President of Finance & Investor Relations | no data | geen gegevens | geen gegevens | |
Senior VP & General Counsel | 5.3yrs | geen gegevens | geen gegevens | |
Senior VP & Chief Human Resources Officer | 2.4yrs | geen gegevens | geen gegevens | |
Senior VP & Chief Development Officer | 4.3yrs | geen gegevens | 0.040% $ 876.3k | |
Senior VP & Head of International | 3.3yrs | geen gegevens | geen gegevens | |
Senior Vice President of Clinical Development | 3.4yrs | geen gegevens | geen gegevens |
4.3yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DCPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 6.1yrs | US$6.01m | 0.084% $ 1.9m | |
Independent Director | 9.3yrs | US$388.59k | 0% $ 0 | |
Independent Director | 7.7yrs | US$396.09k | 0% $ 0 | |
Independent Director | 7.8yrs | US$398.55k | 0% $ 0 | |
Independent Chairman | 4.5yrs | US$403.30k | 0% $ 0 | |
Member of Scientific Advisory Board | 9yrs | geen gegevens | geen gegevens | |
Independent Director | 16.8yrs | US$414.77k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 9yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 9yrs | geen gegevens | geen gegevens | |
Independent Director | 9.3yrs | US$386.05k | 0.013% $ 281.5k | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
9.0yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DCPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).